Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells $31,185.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) Director Duncan Gallagher sold 4,500 shares of the stock in a transaction on Monday, December 30th. The stock was sold at an average price of $6.93, for a total value of $31,185.00. Following the sale, the director now owns 69,938 shares of the company's stock, valued at approximately $484,670.34. This represents a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Duncan Gallagher also recently made the following trade(s):

• On Monday, December 23rd, Duncan Gallagher sold 4,500 shares of Health Catalyst stock. The shares were sold at an average price of $6.98, for a total value of $31,410.00.

Health Catalyst Trading Up 3.8 %

HCAT traded up $0.27 during mid-day trading on Thursday, hitting $7.34. The stock had a trading volume of 338,216 shares, compared to its average volume of 542,543. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The firm has a market capitalization of $446.64 million, a price-to-earnings ratio of -5.44 and a beta of 1.31. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock's fifty day simple moving average is $7.87 and its 200-day simple moving average is $7.48.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.22) earnings per share. As a group, research analysts forecast that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds have recently bought and sold shares of HCAT. First Light Asset Management LLC boosted its stake in Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company's stock valued at $25,279,000 after purchasing an additional 3,221,408 shares during the period. Impax Asset Management Group plc boosted its position in shares of Health Catalyst by 16.4% in the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company's stock valued at $20,793,000 after acquiring an additional 360,201 shares during the period. Millennium Management LLC grew its stake in shares of Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company's stock valued at $15,421,000 after acquiring an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA grew its stake in shares of Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company's stock valued at $19,572,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Daventry Group LP increased its position in Health Catalyst by 3.9% during the second quarter. Daventry Group LP now owns 2,247,053 shares of the company's stock worth $14,359,000 after acquiring an additional 84,178 shares during the period. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HCAT. Citigroup boosted their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. upped their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Wednesday, September 4th. Royal Bank of Canada lifted their price objective on Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a research note on Thursday, November 7th. Piper Sandler restated an "overweight" rating and set a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Finally, Stephens lifted their price target on Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $11.79.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.